Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
about
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondEfficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor AgonistsSystematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.DPP-4 inhibitors: focus on safety.Albiglutide: a review of its use in patients with type 2 diabetes mellitus.Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.Controlled release of biologics for the treatment of type 2 diabetes.Half-life extended biotherapeutics.Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model.Albiglutide: a unique GLP-1 receptor agonist.Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.The safety of albiglutide for the treatment of type 2 diabetes.Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.Incretin manipulation in diabetes management.Albiglutide-induced pancreatitis.A streamlined cloning workflow minimising the time-to-strain pipeline for Pichia pastoris.No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide.Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
P2860
Q26799389-74A0B1A2-DB19-45EC-8614-E5DF7AC6A438Q31082841-8C4A3129-FB02-4E31-B658-A9B0CDEDB135Q36073461-08194E99-9838-4A21-89BB-0501BD3E51FBQ37729181-35256CA6-AEAB-48F4-9783-1DBA03B72726Q38285608-C07EA3B0-A5E6-4CD1-A225-B21BED9305C8Q38380559-53192D08-FDA0-4890-98D3-EF2E4B0FB1DCQ38542098-0CCB9FD9-1A7E-439B-BEC3-E61358BED41CQ38602769-8A531AB5-DF3B-4CD8-AE0A-69EB0C843DD3Q38665753-CBA6FBBF-8956-43F1-9513-0C6FE9DB9432Q38770067-47406E0C-4A05-48D9-9D35-33FC8EA2B745Q38838461-B13A671E-E824-47CC-AEBB-882CB5FF6816Q38884947-8B983682-0F61-4DA6-AB85-EF10E17DA683Q38966029-25F226FB-61AA-4AA0-A824-493386E05B7AQ39041615-CE49A04B-BCAE-4C8F-9683-8AE9A3883646Q39415439-699E631D-28E3-451D-923E-32628EEF3CA9Q40745963-C21396F3-91A7-45E8-9D44-012216C9756BQ41906284-B48E4657-1443-47FB-8650-E650503A2E24Q42365383-3A7A58FA-2DAF-4FC9-8BCA-EFB6F38F9386Q47137573-15195CBF-B8DA-4915-B6AB-0C961A5DE4C4Q48345845-7A1385C9-9ACE-4C2D-B6B1-84427A6E92F4Q52663655-D574F2F3-C430-42B1-90DA-9CC4BE5240B7
P2860
Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
@en
type
label
Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
@en
prefLabel
Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
@en
P2860
P356
P1476
Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
@en
P2093
Jennifer M Trujillo
Wesley Nuffer
P2860
P304
P356
10.1177/1060028014545807
P407
P577
2014-08-18T00:00:00Z